Value of [18F]FDG PET/CT for predicting epidermal growth factor receptor gene mutation status in patients with newly diagnosed non-small cell lung cancer: a retrospective single center study
Open Access
- 16 June 2025
- journal article
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (2) , 46-59
Abstract
Purpose of the study. The aim of this study was to evaluate the role of [18F]FDG PET/CT for predicting epidermal growth factor receptor (EGFR) gene mutation status in patients with newly diagnosed non-small cell lung cancer (NSCLC).Patients and methods. This retrospective single center study included 63 patients with NSCLC who underwent [18F]FDG PET/ CT and were divided into the mutant (n = 30) and wild-type groups (n = 33) based on EGFR mutation status. Maximal diameter (Dmax) and anatomical volume of each primary tumor lesion were measured, [18F]FDG uptake was analyzed by measurement of SUVmax, SUVpeak, MTV, TLG and TLR. TLG was measured using PET segmentation method by 3D-Isocontour tool with 41 % of SUVmax threshold (TLG41 %) and threshold adapted to the anatomical volume (TLGCT). Acquisition data of NEMA IEC Body Phantom Set NU2–2018 was applied for plotting the recovery coefficients curves that used for following partial volume effect correction (without correction – PVE, after correction – cPVE).Results. Medians of lesions’ metrics in the mutant and wild-type groups were, respectively: Dmax – 3 [2.5; 4] and 3.6 [2.5; 4.4] cm, p > 0.05; anatomical volume – 7 [5.2; 14.7] and 12.1 [4.6; 24.4] ml, p > 0.05; PVE SUVmax – 6.6 [3.6; 9.3] and 8.5 [6.4; 10], p > 0.05; cPVE SUVmax – 5.7 [3.2; 7.6] and 6.8 [5.4; 8.1], p > 0.05; PVE SUVpeak – 5.7 [2.8; 7.6] and 6.6 [5.2; 8.8], p > 0.05; cPVE SUVpeak – 5.2 [3; 6.8] and 6.7 [4.7; 7.7], p > 0.05; PVE MTV41 % – 5.4 [3.3; 10.4] and 9 [3.6; 16.2], p > 0.05; cPVE MTV41 % – 5.2 [3.3; 10.1] and 6.2 [3.6; 11.7], p > 0.05; PVE TLG41 % – 21.5 [9.2; 37.8] and 36.9 [10.2; 78], p > 0.05; cPVE TLG41 % – 28.9 [16; 46.4] and 24.9 [12.9; 66.4], p > 0.05; PVE TLGCT – 27.8 [11.5; 52.1] and 54.7 [14.4; 123], p > 0.05; cPVE TLGCT – 31 [14.7; 51.7] and 35.8 [16.2; 82.6], p > 0.05; PVE TLR – 3 [2; 5.2] and 4 [3; 5.3], p > 0.05; cPVE TLR – 3 [2.1; 4.5] and 3.6 [2.7; 5], p > 0.05.Conclusion. Our results suggest that [18F]FDG PET/CT has no significant value for predicting the EGFR gene mutation status in patients with newly diagnosed NSCLC.Keywords
This publication has 16 references indexed in Scilit:
- Can18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysisBMJ Open, 2021
- Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancerOncotarget, 2017
- 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancerMedicine, 2016
- Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancerBMC Cancer, 2016
- Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerThe Oncologist, 2011
- 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysisLung Cancer, 2010
- Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinomaMedical Oncology, 2009